Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Korea's Ilyang Pharmaceutical Starts Phase III Trials For First-line CML Drug To Compete With Gleevec

This article was originally published in PharmAsia News

Executive Summary

SEOUL - South Korea's Ilyang Pharmaceutical Co. Ltd. recently started Phase III trials for novel leukemia drug Supect (rodotinib) in Korea, India, Thailand, Philippines and Indonesia to determine whether it can gain approval in Korea as a first-line treatment for chronic myeloid leukemia and take on Novartis AG's Gleevec (imatinib). The company aspires to then bring the product to other Asian markets, and then eventually the U.S
Advertisement

Related Content

Korea’s Ilyang Wins KFDA Approval For 2nd-Line Leukemia Drug Supect; Could Compete With Gleevec
Korea's Health Ministry Gets In The Act To Generate Korean Innovation For U.S. Markets
Korea's Health Ministry Gets In The Act To Generate Korean Innovation For U.S. Markets
OECD Recommends Changes in Korea's Healthcare System In Its First Survey Of Korea's Pharma Sector
South Korea Will Not Pursue Compulsory Licensing Against MNCs, But For How Long?
Advertisement
UsernamePublicRestriction

Register

SC078829

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel